GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: ACTIV-3

In this photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis, Ind. On Monday, U.S. government officials announced they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it is unlikely to help.

Eli Lilly Ends Antibody Trial In Hospitalized COVID-19 Patients, Other Trials Go On

The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."

|
By:
  • Vanessa Romo